You just read:

OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries

News provided by

OncoSec Medical Incorporated

Oct 10, 2019, 08:30 ET